Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome
New England Journal of Medicine, Volume 351, No. 9, Year 2004
Notification
URL copied to clipboard!
Description
BACKGROUND: Preclinical studies suggest that exogenous surfactant may be of value in the treatment of the acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward benefit. We conducted two phase 3 studies of a protein-containing surfactant in adults with ARDS. METHODS: In two multicenter, randomized, double-blind trials involving 448 patients with ARDS from various causes, we compared standard therapy alone with standard therapy plus up to four intratracheal doses of a recombinant surfactant protein C-based surfactant given within a period of 24 hours. RESULTS: The overall survival rate was 66 percent 28 days after treatment, and the median number of ventilator-free days was 0 (68 percent range, 0 to 26); there was no significant difference between the groups in terms of mortality or the need for mechanical ventilation. Patients receiving surfactant had a significantly greater improvement in blood oxygenation during the initial 24 hours of treatment than patients receiving standard therapy, according to both univariate and multivariate analyses. CONCLUSIONS: The use of exogenous surfactant in a heterogeneous population of patients with ARDS did not improve survival. Patients who received surfactant had a greater improvement in gas exchange during the 24-hour treatment period than patients who received standard therapy alone, suggesting the potential benefit of a longer treatment course. © 2004 Massachusetts Medical Society.
Authors & Co-Authors
Spragg, Roger G.
United States, La Jolla
University of California, San Diego
Lewis, James F.
Canada, London
Western University
Walmrath, Hans Dieter
Germany, Giessen
Justus-liebig-universität Gießen
Johannigman, Jay A.
United States, Cincinnati
University of Cincinnati
Bellingan, Geoff
United Kingdom, London
University College London
Laterre, Pierre François
Belgium, Brussels
Cliniques Universitaires Saint-luc
Witte, Michael C.
United States, Des Moines
Mercy Medical Center Des Monies
Richards, Guy Antony
South Africa, Johannesburg
University of the Witwatersrand
Rippin, Gerd
Germany, Koln
Omnicare Clinical Research
Rathgeb, Frank
Germany, Konstanz
Altana Pharma Deutschland Gmbh
Häfner, Dietrich
Germany, Konstanz
Altana Pharma Deutschland Gmbh
Taut, Friedemann J.H.
Germany, Konstanz
Altana Pharma Deutschland Gmbh
Seeger, Werner
Germany, Giessen
Justus-liebig-universität Gießen
Statistics
Citations: 13
Authors: 13
Affiliations: 10
Identifiers
Doi:
10.1056/NEJMoa033181
ISSN:
00284793
Research Areas
Disability
Study Design
Cross Sectional Study